Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552571 | 0.77 | TDP1 (0.42) | TDP1HSP90AA1ATMNMT1UBE2N | |
| SCHEMBL21252647 | 0.77 | — | — | |
| SCHEMBL18430927 | 0.73 | TDP1 (0.38) | TDP1HSP90AA1ATMNMT1UBE2N | |
| SCHEMBL12590718 | 0.73 | TDP1 (0.38) | TDP1HSP90AA1ATMNMT1UBE2N | |
| SCHEMBL378803 | 0.71 | — | — | |
| SCHEMBL13743863 | 0.71 | GRM5 (0.45) | TDP1HSP90AA1ATMNMT1PSMD14 | |
| SCHEMBL6208653 | 0.71 | TDP1 (0.52) | TDP1HSP90AA1ATMNMT1UBE2N | |
| SCHEMBL31014345 | 0.67 | IDO1 (0.31) | IDO1 | |
| SCHEMBL22535086 | 0.67 | NMT1 (0.35) | TDP1HSP90AA1ATMNMT1UBE2N | |
| SCHEMBL12461186 | 0.67 | TDP1 (0.46) | TDP1HSP90AA1ATMNMT1UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| CN-103467385-B | Bicyclic heteroaryl compounds | ARIAD GENE THERAPEUTICS INC. (US) | 2016-03-09 | — | — | CN | disclosed |
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| CN-101918362-B | Pyridine derivatives | NOVARTIS AG | 2013-11-27 | — | — | CN | disclosed |
| WO-2013159135-A1 | DISPERSION INK | SEPIAX INK TECHNOLOGY GMBH (AT) | 2013-10-31 | — | — | WO | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| CN-101918362-A | Pyridine derivatives | NOVARTIS AG | 2010-12-15 | — | — | CN | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2024366-A2 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133562-A2 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | TDP1 4626/4885HSP90AA1 4130/4885ATM 4513/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | TDP1 4450/4885HSP90AA1 4271/4885ATM 4679/4885 |
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | TDP1 3297/4885HSP90AA1 4151/4885ATM 3042/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | TDP1 4450/4885HSP90AA1 4271/4885ATM 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.